1.
ARTIFICIAL INTELLIGENCE, SYSTEM ANALYSIS AND SIMULATION
MODELING IN OPTIMIZATION OF LUNG CANCER TREATMENT
Oleg Kshivets, Siauliai, Lithuania, 5th EACTS/ESTS JOINT MEETING, 9-13 September 2006, Stockholm, Sweden
METHODS: In trial (1985-2006) the data It was revealed that 5YS and LS of LCP
of consecutive 425 LCP (age=56.4; after resections significantly depended on:
m=382, f=43; D=4.4 cm; pn=185, lob=240, 1) phase transition "early LC-invasive LC";
comb=63; sq=274, ad=124, lcl=27; 2) level of blood cell subpopulations circuit;
T1=124, T2=196, T3=86, T4=19; N0=234, 3) ratio LC cells/blood cell subpopulations;
N1=104, N2=87) was reviewed. Neural
4) LC characteristics;
networks computing, Cox regression,
clustering, discriminant analysis, structural 5) hemostasis system;
equation modeling, Monte Carlo and 6) biochemic data;
bootstrap simulation were used to 7) hematological factors;
determine any significant regularity. 8) procedure type; anthropometric data.
RESULTS: Overall LS=1674.5±54.1 days Correct prediction of LCP survival after
and 5YS reached 59.1%. 251 LCP lived complete pneumonectomies and
more than 5 years (LS=2446.7±46.5 days). lobectomies (R0) was 84% by logistic
174 LCP died because of LC during first 5 regression, 85.8% by discriminant analysis
years after surgery (LS=560.8±29.2 days). and 100% by neural networks computing
Cox Regression: Prediction of 5-Year Survival of Lung Cancer Patients after Complete Resections (n=425)
95.0% CI for Exp(B)
(error=0.0017; urea under ROC curve=1.0).
AGE
WEIGHT
B
.015
-.007
SE
.007
.005
Wald
4.155
1.821
df
1
1
Sig.
.042
.177
Exp(B)
1.015
.993
Lower
1.001
.984
Upper
1.029
1.003
Cumulative Proportion Surviving (Kaplan-Meier)
Complete Censored
Survival of Lung Cancer Patients with N1-2 (n=191)
CONCLUSIONS: Optimal
GROWTH .163 .111 2.164 1 .141 1.177 .947 1.463
treatment strategies for lung
P=0.0007 by Log Rank Test
HISTOLOGY .053 .070 .572 1 .449 1.054 .920 1.208
G1-3 .067 .065 1.049 1 .306 1.069 .941 1.214 1.0
T1-4 .172 .089 3.769 1 .050 1.188 .998 1.413
Cumulative Proportion Surviving
0.9
Without Adjuvant CHIRT, n=152
N0-2
TUMOR SIZE
ERYTHROCYTES
.343
.023
-.182
.070
.037
.111
24.102
.388
2.662
1
1
1
.000
.533
.103
1.410
1.023
.834
1.229
.952
.670
1.617
1.100
1.037
0.8
0.7
0.6
Adjuvant CHIRT, n=39
cancer patients are:
THROMBOCYTES .002 .001 2.442 1 .118 1.002 .999 1.005
0.5
LEUCOCYTES
1) screening and early detection of
-.048 .024 3.893 1 .048 .953 .909 1.000
STICK NEUTROPHILS -.065 .027 6.072 1 .014 .937 .889 .987 0.4
LYMPHOCYTES -.021 .006 12.401 1 .000 .979 .968 .991 0.3
ESS -.008 .005 3.059 1 .080 .992 .983 1.001 0.2
GLUCOSE
PROTHROMBIN INDEX
BILIRUBIN
-.085
.026
.037
.058
.006
.018
2.117
16.778
4.118
1
1
1
.146
.000
.042
.918
1.026
1.037
.819
1.014
1.001
1.030
1.039
1.075
0.1
0 2 4 6 8 10
Years after Pneomonectomies & Lobectomies
12 14 16 18 lung cancer;
PROTEIN -.010 .008 1.676 1 .195 .990 .976 1.005
RECALCIFICATION TIME
FIBRINOGEN
HEPARIN TOLERANCE
-.004
.057
.003
.001
.038
.001
6.672
2.329
31.258
1
1
1
.010
.127
.000
.996
1.059
1.003
.993
.984
1.002
.999
1.140
1.005
Training Error Graph (Sum-squared)
Prediction of 5-Year Survival of LCP (n=425)
2) aggressive en block surgery for
Cox Regression: Prediction of 5-Year Survival of Lung Cancer Patients after Complete Resections (n=425)
95.0% CI for Exp(B)
Network: 10 (MLP)
Baseline Error=0.0017; Correct Classification Rate=100%
Area Under ROC Curve=1.00
completeness;
B SE Wald df Sig. Exp(B) Lower Upper 0.6
THROMBOCYTES/CANCER CELL
LEUCOCYTES/CANCER CELLS
STICK NEUTROPHILS/CANCER C
-.010
-.790
1.552
.003
.479
1.156
10.265
2.717
1.803
1
1
1
.001
.099
.179
.991
.454
4.721
.985
.178
.490
.996
1.161
45.499 0.4
Train by Levenberg-Marquardt
3) precise prediction;
SEGM.NEUTROPHILS/CANCER C .861 .515 2.794 1 .095 2.365 .862 6.490
4) adjuvant CHIRT for lung cancer
Error
LYMPHOCYTES/CANCER CELLS .885 .577 2.353 1 .125 2.424 .782 7.513
NORM CELLS/CANCER CELLS .117 .039 8.901 1 .003 1.125 1.041 1.215
0.2
THROMBOCYTES (tot) .003 .001 13.951 1 .000 1.003 1.001 1.004
LEUCOCYTES (tot)
STIC NEUTROPHILS (tot)
SEGMENTED NEUTROPHILS (tot
.192
-.603
-.327
.130
.302
.148
2.172
3.980
4.866
1
1
1
.141
.046
.027
1.212
.547
.721
.939
.303
.539
1.564
.989
.964
0.0
0 10 20 30 40 50 60
patients with unfavorable
prognosis.
LYMPHOCYTES (tot) -.298 .158 3.565 1 .059 .742 .545 1.011 Epoch
SEGMENTED NEUTROPHILS (abs .608 .171 12.634 1 .000 1.836 1.313 2.566
Poster Nr.